EC Number   |
Protein Variants |
Reference |
|---|
    1.5.1.3 | A16V |
point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine |
703160, 703329 |
| 1.5.1.3 | A16V/N51I/C59R/S108N |
point mutations of the active site residues lead to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine, binding structure modelling, overview |
703329 |
| 1.5.1.3 | A31K |
site-directed mutagenesis |
392291 |
| 1.5.1.3 | A71V |
mutation confers resistance to antimalarial DHFR inhibitor drug cycloguanil, mutation is in the DHFR domain, close to the binding sites for DHF |
765575 |
| 1.5.1.3 | C59R |
point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine |
703160, 703329 |
| 1.5.1.3 | C59R/S108N |
mutant with increased resistance to anitfolate antimalarials, use for screening inhibitors |
671315 |
| 1.5.1.3 | C59R/S108N |
point mutations of the active site residues lead to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine, binding structure modelling, overview |
703329 |
| 1.5.1.3 | C829T |
naturally occurring single nucleotide polymorhism , near the miR-24 binding site in the 3' UTR of human dihydrofolate reductase leads to a decrease in microRNA binding, which in turn leads to overexpression of its target and results in resistance to methotrexate |
689753 |
| 1.5.1.3 | C85A/C152S |
kinetic properties similar to wild-type |
674549 |
| 1.5.1.3 | C85S/C152E |
cysteine-free mutant, analysis of inhibition by p.eroxynitrite. bicarbonate buffer protects mutant from inhibition by peroxynitrite. Decrease in mutant stability upon oxidation |
671581 |
